Abstract:Sickle cell disease (SCD) is a genetic disorder predominantly affecting individuals of African descent, with a significant global health burden. SCD is characterized by intravascular hemolysis, driven by the polymerization of mutated hemoglobin within red blood cells (RBCs), leading to vascular inflammation, organ damage, and heme toxicity. Clinical manifestations include acute pain crises, hemolytic anemia, and multi-organ dysfunction, imposing substantial morbidity and mortality challenges. Current therapeutic strategies mitigate these complications by increasing the concentration of RBCs with normal hemoglobin via transfusion, inducing fetal hemoglobin, restoring nitric oxide signaling, inhibiting platelet-endothelium interaction, and stabilizing hemoglobin in its oxygenated state. While hydroxyurea and gene therapies show promise, each faces distinct challenges. Hydroxyurea's efficacy varies among patients, and gene therapies, though effective, are limited by issues of accessibility and affordability. An emerging frontier in SCD management involves harnessing endogenous clearance mechanisms for hemolysis products. A recent work by Heggland et al. showed that CD-36-like proteins mediate heme absorption in hematophagous ectoparasite, a type of parasite that feeds on the blood of its host. This discovery underscores the need for further investigation into scavenger receptors (e.g., CD36, SR-BI, SR-BII) for their possible role in heme uptake and detoxification in mammalian species. In this review, we discussed current SCD therapeutics and the specific stages of pathophysiology they target. We identified the limitations of existing treatments and explored potential future developments for novel SCD therapies. Novel therapeutic targets, including heme scavenging pathways, hold the potential for improving outcomes and reducing the global burden of SCD.

Blood rheology and vascular function in sickle cell trait and sickle cell disease: From pathophysiological mechanisms to clinical usefulness

Vascular pathophysiology of sickle cell disease

Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction

Biomechanics and biorheology of red blood cells in sickle cell anemia

Exercise and training in sickle cell disease: Safety, potential benefits, and recommendations

Sickle cell disease as a vascular disorder

Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease

Sickle Cell Disease: From Genetics to Curative Approaches

Patient-Specific Blood Rheology In Sickle-Cell Anaemia

In Vivoevaluation of the Effect of Sickle Cell Hemoglobin S, C and Therapeutic Transfusion on Erythrocyte Metabolism and Cardiorenal Dysfunction

In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction

Exercise‐induced erythrocyte dysfunction in individuals with sickle cell trail (547.1)

Role of Exercise-Induced Oxidative Stress in Sickle Cell Trait and Disease

Therapeutics for sickle cell disease intravascular hemolysis

Does physical activity increase or decrease the risk of sickle cell disease complications?

Less Deformable Erythrocyte Subpopulations Biomechanically Induce Endothelial Inflammation in Sickle Cell Disease

Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review

Understanding Exercise (in)tolerance in Sickle Cell Disease: Impacts of Hemolysis and Exercise Training on Skeletal Muscle Oxygen Delivery

Curative Therapies for Sickle Cell Disease

A critical review of therapeutic interventions in sickle cell disease: Progress and challenges

Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target